SecBot SecBot
PRESS-RELEASE ·Filed May 18, 2026

BWAY

BrainsWay
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

The dollar amounts are too small to change BrainsWay's core commercial trajectory. Monitor future quarters for evidence that these clinic partnerships actually drive incremental Deep TMS system placements and utilization, without that, this is just a passive financial investment. No material near-term catalyst.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$14.88
T+0 close · May 18, 2026 · via day close
Latest settled
+11.56%
T+60 · $16.60
Vs SPY
+6.71%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $14.88entry
  2. T+1 · 6mo ago +0.07%α +0.72% · $14.89
  3. T+5 · 6mo ago +6.79%α +5.17% · $15.89
  4. T+20 · 5mo ago −5.04%α −6.62% · $14.13
  5. T+60 · 3mo ago +11.56%α +6.71% · $16.60

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BrainsWay announced a strategic minority investment of $1.5M (with potential $1.5M in milestone-based investments) in Hopemark Health, a Chicago-area mental health clinic network. This is a small, structured equity deal that reinforces BrainsWay's strategy of deepening clinical partnerships for Deep TMS adoption, but the financial commitment is very modest relative to the company's enterprise value.

Key Financial Metrics

Deal Value
$1.5M

Key Facts

  • BrainsWay invests $1.5M1.5 initially, up to $3.0M total including milestones, for a minority stake in Hopemark Health
  • The investment takes the form of a preferred, annually compounding security with a redemption mechanism
  • Hopemark operates multiple mental health clinics in the greater Chicago area, including ketamine-based therapies
  • This continues BrainsWay's strategy of minority investments in growth-oriented clinical platforms to expand Deep TMS access

Financial Impact

$1.5M initial investment with another $1.5M in milestone tranches; total cap $3.0M, immaterial relative to BrainsWay's market cap

cash

Risk Factors

  • Investment size is tiny, fails to move the needle on revenue or earnings
  • Minority stake with redemption mechanism provides no operational control; returns depend on Hopemark's execution
  • Forward-looking statements about partnership benefits are non-binding marketing language

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3296520

US Market Status

Market Closed · Opens Wed (11h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026